Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
A developer-targeting campaign leveraged malicious Next.js repositories to trigger a covert RCE-to-C2 chain through standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results